BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2018 10:51:22 AM | Browse: 1018 | Download: 1488
 |
Received |
|
2018-09-19 05:57 |
|
Peer-Review Started |
|
2018-09-19 08:13 |
|
To Make the First Decision |
|
2018-10-17 01:44 |
|
Return for Revision |
|
2018-10-18 00:40 |
|
Revised |
|
2018-10-24 14:23 |
|
Second Decision |
|
2018-11-23 11:17 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-11-26 05:28 |
|
Articles in Press |
|
2018-11-26 05:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-12-06 10:24 |
|
Publish the Manuscript Online |
|
2018-12-14 10:51 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Moon Jae Chung, Huapyong Kang, Ho Gak Kim, Jong Jin Hyun, Jun Kyu Lee, Kwang Hyuck Lee, Myung Hwan Noh, Dae Hwan Kang, Sang Hyub Lee and Seungmin Bang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Seungmin Bang, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. bang7028@yuhs.ac |
| Key Words |
Pancreatic cancer; FOLFIRINOX; Clinical Trial, Phase Ⅱ; Chemotherapy; Gemcitabine refractory |
| Core Tip |
For gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC), there are limited options of second-line chemotherapy regimen. To find new treatment option for GEM-refractory unresectable PC, we conducted a multicenter phase Ⅱ trial, which evaluated the efficacy and safety of uniquely modified FOLFIRINOX with reduced irinotecan and oxaliplatin. In our results, FOLFIRINOX with reduced irinotecan and oxaliplatin showed acceptable toxicity and promising efficacy. With careful observation of treatment-related hematologic toxicities, this chemotherapy regimen is a promising option for patients with GEM-refractory PC after first-line treatment failure. |
| Publish Date |
2018-12-14 10:51 |
| Citation |
Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabin-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 |
| URL |
https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v10.i12.505 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
